First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAHSAN DIEGO, Jan. 22, 2026(Nasdaq: CRNX) today anno ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results